Anticancer Therapies – News and Features

A new drug currently in trials for ovarian and bile duct cancer may also treat hormone therapy-resistant prostate cancer.

The adaptive immune system is highly complex and specific. In this article we focus on T cells, and discuss their development, their different functions, and what happens when they don't function correctly.

Researchers have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors.

UC researchers reveal that miR-205 regulates MED1 and HER3, proteins driving breast cancer treatment resistance. Boosting miR-205 levels could block MED1 production and activity, enhancing therapy outcomes.

Researchers have revealed a previously unknown mechanism that triggers an inflammatory immune response in cells when their DNA is damaged.

Research into cancer-associated fibroblasts could make cancer immunotherapy more effective.

Nearly half of high-risk prostate cancer patients classified as nonmetastatic by traditional imaging show metastases when evaluated with PSMA-PET scans, a UCLA study finds. This advanced imaging technique uncovers hidden cancer spread.

UC San Diego researchers reveal key differences in PD-1 checkpoint receptors between rodents and humans. Rodent PD-1 is significantly weaker, traced to evolutionary adaptations 66 million years ago.

Oleanolic acid, found in grapes, could increase the effectiveness of chemotherapy, reducing the amount of drug needed.

Researchers developed a dual-vector "zip-sorting" system, doubling the genetic capacity of CAR T cells to combat tumor resistance. This enables T cells to target multiple antigens, reduce exhaustion via switch receptors and resist immune suppression.